Nabieva, N., Kellner, S., Fehm, T., Haebrle, L., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H. -C., Guggenberger, M., Warm, M., Harbeck, N., Wuerstlein, R., Deuker, J. -U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. -W., Breitbach, G. -P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesselt, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Brucker, S. Y., Kuemmel, S., Beckmann, M. W., Wallwiener, D., Hadji, P. and Fasching, P. A. (2018). Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. Ann. Oncol., 29 (1). S. 186 - 193. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Full text not available from this repository.

Abstract

Background: Patients' compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature cessation of therapy, on the basis of patient and tumor characteristics in individuals receiving adjuvant treatment with letrozole. Patients and methods: The EvAluate-TM study is a prospective, multicenter, noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive EBC in the early therapy phase. Treatment persistence was evaluated at two pre-specified study visits after 6 and 12 months. As a measure of early therapy persistence the time from the start to the end of treatment (TTEOT) was analyzed. Cox regression analyses were carried out to identify patient characteristics and tumor characteristics predicting TTEOT. Results: Out of the total population of 3941 patients with EBC, 540 (13.7%) events involving treatment cessation unrelated to disease progression were observed. This was due to drug-related toxicity in the majority of cases (73.5%). Persistence rates were 92.2%, 86.9%, and 86.3% after 6, 12, and 15 months, respectively. The main factors influencing premature treatment discontinuation were older age [hazard ratio (HR) 1.02/year], comorbidities (HR 1.06 per comorbidity), low body mass index, and lower tumor grade (HR 0.85 per grade unit). Conclusion: These results support the view that older, multimorbid patients with low tumor grade and low body mass index are at the greatest risk for treatment discontinuation and might benefit from compliance and support programs.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Nabieva, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kellner, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fehm, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haebrle, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Waal, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rezai, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baier, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baake, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kolberg, H. -C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Guggenberger, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Warm, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Harbeck, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wuerstlein, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Deuker, J. -U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dall, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Richter, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wachsmann, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brucker, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Siebers, J. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fersis, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuhn, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vollert, H. -W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Breitbach, G. -P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Janni, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Landthaler, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kohls, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rezek, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Noesselt, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Henschen, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Praetz, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heyl, V.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuehn, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krauss, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thomssen, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hohn, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tesch, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mundhenke, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hein, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rauh, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bayer, C. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jacob, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmidt, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Belleville, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brucker, S. Y.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuemmel, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beckmann, M. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wallwiener, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hadji, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fasching, P. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-200011
DOI: 10.1093/annonc/mdx630
Journal or Publication Title: Ann. Oncol.
Volume: 29
Number: 1
Page Range: S. 186 - 193
Date: 2018
Publisher: OXFORD UNIV PRESS
Place of Publication: OXFORD
ISSN: 1569-8041
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ADJUVANT HORMONAL-THERAPY; ENDOCRINE THERAPY; EARLY DISCONTINUATION; AROMATASE INHIBITORS; ANASTROZOLE THERAPY; RANDOMIZED-TRIAL; TAMOXIFEN; ADHERENCE; RISK; NONADHERENCEMultiple languages
OncologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/20001

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item